Bio-Rad Laboratories B

Jefferies cuts Bio-Rad Labs target to $285, maintains Hold

On Friday, Jefferies adjusted its outlook on Bio-Rad Laboratories stock, lowering the price target to $285 from the previous $315, while keeping a Hold rating on the shares. The...

Bio-Rad Laboratories Inc receives Investment Bank Analyst Rating Update

Bio-Rad stock touches 52-week low at $243.94 amid market shifts

In a challenging market environment, Bio-Rad Laboratories Inc (NYSE:BIO). stock has reached a 52-week low, dipping to $243.94. According to InvestingPro data, the company...

Bio-Rad stock touches 52-week low at $248.05 amid market shifts

Bio-Rad Laboratories Inc (NYSE:BIO), a notable player in the life science research and clinical diagnostics markets, has seen its stock price touch a 52-week low, reaching...

Bio-Rad stock touches 52-week low at $262.11 amid market shifts

In a challenging market environment, Bio-Rad Laboratories Inc (NYSE:BIO). stock has recorded a 52-week low, dipping to $262.11. With a current ratio of 6.48, the company...

Bio-Rad Laboratories Inc receives Investment Bank Analyst Rating Update

Bio-Rad Laboratories Inc receives Investment Bank Analyst Rating Update

Bio-Rad Laboratories Inc receives Investment Bank Analyst Rating Update

Bio-Rad Labs B earnings beat by $0.04, revenue fell short of estimates

Investing.com - Bio-Rad Labs B (NYSE: BIOb) reported fourth quarter EPS of $2.90, $0.04 better than the analyst estimate of $2.86. Revenue for the quarter came in at $667.5M versus...

Earnings call transcript: Bio-Rad Q4 2024 results miss forecasts

Bio-Rad Laboratories Inc (NYSE:BIO). reported its fourth-quarter 2024 earnings, revealing a slight miss on revenue expectations, with net sales of $668 million compared to a...